This is an amended filing · View original →
[Amended] Single Sales/Supply Contract
AAI summary · Not investment advice
Abion amended its supply contract disclosure with the Agency for Defense Development for antibody detoxification platform research, adding payment timing; delivery is fully complete.
Contract amount
KRW 1.7 billion
Key facts
- Recent revenue
- KRW 1.3 billionBased on consolidated financial statements at end of 2023
- % of revenue
- 136.25%
- Counterparty
- Agency for Defense Development
- Contract details
- Research and technology development of an antibody detoxification platform
- Contract period
- Apr 11, 2024 – Oct 31, 2026
- Contract date
- Apr 11, 2024
Commentary
AI commentary · Not investment advice
What happened
Abion disclosed a single sales and supply contract with the Agency for Defense Development for antibody decoding platform research and technology development. The contract amount is KRW 1.7 billion, signed on 2024.04.11, with a contract period from 2024.04.11 to 2026.10.31. This filing adds a payment receipt schedule to the existing contract, and all deliveries have been completed.
In the company's terms
Relative to the company, the contract amount equals 136.25% of its most recent revenue of KRW 1.3 billion. It is stated as 2.9% of market capitalization.
What changes for shareholders
The filing was received on 2026.10.30.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist